Issues in Transfusion Therapy in the Patient With Malignancy

Friedberg, Richard

doi:10.1016/s0889-8588(18)30131-x

Cited by 6 publications

(4 citation statements)

References 183 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exclusion criteria include: (1) pregnancy and lactation, (2) participating any clinical trial within 3 months before the first dose of the investigational agents, (3) severe or refractory hypertension, (4) the patients with cardiac infarction, stroke, instable angina pectoris, incompensative congestive cardiac failure, or risk of deep vein thrombosis such as previous venous thrombosis history, (5) acute or chronic blood loss history within 3 months before study, (6) allergy to erythropoietin-b, (7) folic acid and vitamin B12 deficiency, (8) erythropoietin treatment within 2 months before the baseline, (9) pure red cell aplastic anemia history, (10) hemolysis, (11) insufficient renal function (serum creatine [29 upper limits), (12) insufficient hepatic function (transaminases [2.59 upper limits, and/or total bilirubin [2 mg/dL), (13) platelet count \50 910 9 L -1 , (14) WBC count \1 9 10 9 L -1 .…”

Section: Patientsmentioning

confidence: 99%

See 1 more Smart Citation

A multi-center open-labeled study of recombinant erythropoietin-β in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin’s lymphoma, or chronic lymphocytic leukemia in Chinese population

Shen

Zhu

et al. 2008

Int J Hematol

View full text Add to dashboard Cite

The purpose of this study is to investigate the efficacy and safety of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma (MM), low-grade non-Hodgkin's lymphoma (NHL), and chronic lymphocytic leukemia (CLL). From December 2005 to November 2006, the patients with MM, low-grade NHL, and CLL were enrolled in this study, male or female, aged > or = 18 years, transfusion-dependant, and receiving anti-neoplasia chemotherapy. Recombinant human erythropoietin-beta was used in this study with the dose initiated at 150 IU/kg, thrice a week, subcutaneously. The total treatment duration was 12 weeks. The primary endpoint of the study is response rate (RR), which is defined as hemoglobin increasing > or = 2 g/dL comparing to baseline level, or returning to normal range, without any transfusion within 6 weeks of evaluation. Fifty out of 82 (64.6%) patients enrolled in this study responded to the treatment and 29 patients had no response. Hypertension (12.2%) is the most common adverse effect; however, all the adverse events were mild, categorized in NCI grade I or II. We conclude that recombinant erythropoietin-beta was effective in the treatment of anemia of the patients with MM, NHL, and CLL, as well as it is well-tolerated.

show abstract

Section: Patientsmentioning

confidence: 99%

“…Transfusion is a direct way to increase hemoglobin; however, its complications such as infection of viral diseases, iron overload, and graft-versus-host reaction [6] could be dangerous. The application of recombinant erythropoietin had provided an alternative modality to correct malignancy-related anemia.…”

mentioning

confidence: 99%

A multi-center open-labeled study of recombinant erythropoietin-β in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin’s lymphoma, or chronic lymphocytic leukemia in Chinese population

Shen

Zhu

et al. 2008

Int J Hematol

View full text Add to dashboard Cite

show abstract

“…However, potentially dangerous complications can be associated with this procedure such as infection, iron overload, acute lung injury, heart failure and graft‐ vs .‐host reactions. Therefore, it is necessary to reduce the number of transfusions and to find another method that increases hemoglobin levels . ESAs are an alternative modality to correct anemia and they have been approved for CAA by the U.S. Food and Drug Administration (FDA).…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, it is necessary to reduce the number of transfusions and to find another method that increases hemoglobin levels. 8 ESAs are an alternative modality to correct anemia and they have been approved for CAA by the U.S. Food and Drug Administration (FDA). They reduce the need for RBC transfusions, increase hemoglobin levels, and improve QoL in patients with CAA.…”

Section: Introductionmentioning

confidence: 99%

The effects of erythropoiesis‐stimulating agents on the management of chemotherapy‐induced anemia and tumor growth in diffuse large B‐cell lymphoma patients

Park

YeonJoo

Kim

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Erythropoiesis‐stimulating agents (ESAs), such as erythropoietin (EPO) and darbepoetin, may alleviate anemia in diffuse large B‐cell lymphoma (DLBCL) patients. However, many cancer cells express EPO receptors (EPOR), through which exogenously administered ESAs potentially promote cancer cell growth. We conducted preclinical/phase II studies to investigate the safety and efficacy of ESAs for managing chemotherapy‐related anemia in DLBCL patients. We examined EPOR expression in germinal center B‐cell (GCB)‐ and activated B‐cell (ABC)‐DLBCL cell lines, and investigated the effects of ESAs on cell proliferation, and rituximab‐mediated complement‐dependent cytotoxicity (CDC). The clinical study enrolled 50 histologically confirmed DLBCL patients receiving rituximab/cyclophosphamide/doxorubicin/vincristine/prednisolone (R‐CHOP) who had hemoglobin levels <10.0 g/dl after a maximum of three R‐CHOP cycles and received ≥4 doses of fixed‐dose darbepoetin (360 μg) once every 3 weeks. EPOR mRNA was detected in all GCB‐DLBCL cell lines, but little/none was detected in ABC‐DLBCL cell lines. GCB‐DLBCL and ABC‐DLBCL cell proliferation was unaffected by EPO or darbepoetin. Rituximab‐mediated CDC of DLBCL cell lines with/without EPOR expression was not affected adversely by EPO. In the clinical study, baseline mean hemoglobin was 9.19 g/dl; the overall mean change in hemoglobin was 1.59 ± 1.3 g/dl (16 weeks). Forty‐eight percent of enrolled patients achieved a hematopoietic response. Our study shows that ESAs do not affect the growth of DLBCL cells or rituximab‐mediated CDC under the experimental conditions that we used, and the appropriate use of ESAs may be effective and safe for DLBCL patients with anemia after R‐CHOP.

show abstract

Transfusion and Stem Cell Support in Cancer Treatment

Wuest¹

1996

Hematology/Oncology Clinics of North America

View full text Add to dashboard Cite

Issues in Transfusion Therapy in the Patient With Malignancy

Cited by 6 publications

References 183 publications

A multi-center open-labeled study of recombinant erythropoietin-β in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin’s lymphoma, or chronic lymphocytic leukemia in Chinese population

A multi-center open-labeled study of recombinant erythropoietin-β in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin’s lymphoma, or chronic lymphocytic leukemia in Chinese population

The effects of erythropoiesis‐stimulating agents on the management of chemotherapy‐induced anemia and tumor growth in diffuse large B‐cell lymphoma patients

Transfusion and Stem Cell Support in Cancer Treatment

Contact Info

Product

Resources

About